Klothea Bio
Miami, US · Founded 2024 · Delaware corporation
Klothea develops mRNA-based therapeutics designed to trigger adjustable and reversible secretion of the Klotho protein, aiming to address the protein deficit linked to age-related diseases. The company uses proprietary mRNA and safe nanocarriers intended for repeated use, and is also evaluating delivery methods such as extracellular vesicles (exosomes).
Founders & leadership
JB
Jeffrey B. MaddenExecutive
OJ
Olivier JarryExecutive
AF
Agustin Fernandez Santana IIINamed on SEC filing
Board
PS
Petr SramekBoard director
WS
Walter SchmidtBoard director
Reported raises · per SEC filings
Form D private placements$5.9M disclosed across 1 round · 2024
▶$5.9MraisedMay 2026 · 18 investors · Other Health CareRule 506(b)
▶$5.9MraisedMay 2026 · 18 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Agustin Fernandez Santana IIIExecutive Officer, Director
- Walter SchmidtDirector
- Petr SramekDirector
- Jeffrey B. MaddenExecutive Officer, Director
- Olivier JarryExecutive Officer
- Offering amount
- $10.4M
- Amount sold
- $5.9M
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Klothea Bio do?
- Klothea develops mRNA-based therapeutics designed to trigger adjustable and reversible secretion of the Klotho protein, aiming to address the protein deficit linked to age-related diseases. The company uses proprietary mRNA and safe nanocarriers intended for repeated use, and is also evaluating delivery methods such as extracellular vesicles (exosomes).
- How much funding has Klothea Bio raised?
- Klothea Bio has disclosed $5.9M raised across 1 round.
- Where is Klothea Bio headquartered?
- Klothea Bio is headquartered in Miami, US.